ArticleEJHaem2026
Reduced Pathogen-Specific T Cell Response With BCMA-Targeted T Cell-Engaging Therapy to Multiple Myeloma.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bispecific antibody (BsAb) treatment can lead to increased infections in myeloma patients. Methods: We used ELISpot and flow cytometry to test the T cell response to BCMA-CD3-bispecific T cell engager (BiTE) pavurutamab (PAV) and BCMA-expressing myeloma cells after in vitro culture. Results: Reduced pathogen-specific responses were found in T cells cultured with PAV yet they killed myeloma cells. In an exploratory study, reduced pathogen-specific memory T cell responses were detected in PBMCs from four myeloma patients responding to BCMA-targeted BsAb therapy. Conclusion: Our preliminary observation and its link to infection should be followed up in a larger study. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.